Haemonetics Corporation (HAE)

Market Cap	3.87B
Revenue (ttm)	1.33B
Net Income (ttm)	168.19M
Shares Out	46.81M
EPS (ttm)	3.44
PE Ratio	23.90
Forward PE	15.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	515,401
Open	81.50
Previous Close	82.11
Day's Range	81.43 - 83.00
52-Week Range	47.32 - 87.32
Beta	0.29
Analysts	Buy
Price Target	88.38 (+6.86%)
Earnings Date	Feb 5, 2026

About HAE

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools....

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 9, 1991
• Employees: 3,023
• Stock Exchange: NYSE
• Ticker Symbol: HAE
• Website: https://www.haemonetics.com

Financial Performance

In 2024, Haemonetics's revenue was $1.36 billion, an increase of 3.95% compared to the previous year's $1.31 billion. Earnings were $167.68 million, an increase of 42.64%.

Analyst Summary

According to 9 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $88.38, which is an increase of 6.86% from the latest price.

Price Target

$88.38

(6.86% upside)

Analyst Consensus: Buy